Common Issues in Peptide Purification And Their Solutions

During peptide purification, a series of typical issues may arise, which can stem from sample pretreatment, mobile phase selection, chromatography resin choice, and purification condition settings. Although multiple challenges can occur during peptide purification, they can be effectively addressed by implementing proper sample pretreatment, selecting suitable mobile phases and chromatography resins, setting appropriate purification conditions, and ensuring cleanliness of the operational environment along with regular column maintenance. These measures can significantly improve purification efficiency and peptide purity.

 

Challenges in Impurity Control

1. Synthetic By-Products：During peptide synthesis, various by-product impurities may be generated, such as deletion peptides – missing one or more amino acids

Insertion peptides – incorporation of incorrect amino acids. Residual protecting groups e.g., incompletely removed Fmoc or Boc groups. Racemization products – conversion of L-amino acids to D-amino acids. These impurities often have physicochemical properties very similar to the target peptide. During purification processes (e.g., HPLC), they may co-elute with the target product due to similar retention times, making effective separation by conventional chromatographic methods challenging. Although many of these impurities are present at very low levels, their structural complexity poses significant analytical challenges. Conventional detection methods (e.g., UV detection) often lack sufficient sensitivity, necessitating the use of high-sensitivity and high-selectivity techniques such as mass spectrometry (MS) or nuclear magnetic resonance (NMR) for accurate identification. This represents a core technical challenge in the development of analytical methods and instrument requirements.

 

Source	Typical impurities	case
1. Synthesis process	Deletion peptides / insertion peptides (amino acid misincorporation),Protecting group residues (e.g., Fmoc, Boc),Side reaction by-products (e.g., racemization, disulfide bond mispairing)	Incomplete deprotection during solid-phase synthesis leads to residual Fmoc protecting groups.
2. Purification process	Incomplete deprotection during solid-phase synthesis leads to residual Fmoc protecting groups.	Acetonitrile residue exceeding limits during reversed-phase chromatography purification.
3. Degradation pathway	Oxidation products (methionine oxidation, disulfide bond cleavage), Hydrolysis products (asparagine deamidation), Aggregates (peptide chain aggregation)	During storage, methionine oxidation generates sulfoxide or sulfone impurities..
4. Formulation and packaging	Excipients-related impurities (antioxidant degradation products), Leachables (plasticizers, rubber vulcanization agents), Photothermal degradation products	Phthalates leaching from injection vials into the drug solution..

 

Table 1: Major processes leading to impurity formation during peptide preparation

• Challenge: Deletion peptides, insertion peptides, oxidation products (e.g., Met oxidation), and racemized isomers are highly similar to the target molecule. High-resolution methods must be selected based on their differences for effective purification. Reversed-phase chromatography is widely used.
• Case: During exenatide purification, ΔGlu15 deletion peptides and Met14O oxidation impurities must be separated.
• Solution: Optimize the synthesis process (e.g., HOBt-DIC coupling to reduce racemization) and combine IEC + RP-HPLC (e.g., GLP-1 class drugs use IEC to capture charge variants).

 

2. Residual Solvents and Genotoxic Impurities: Reversed-phase chromatography is a commonly used technique for peptide purification, but chromatographic media (e.g., silica) may slowly dissolve under high pressure or specific pH conditions, releasing leachables such as metal ions (e.g., iron, aluminum) into the product. Meanwhile, the large amounts of organic solvents used during purification (e.g., acetonitrile, DMF) can lead to excessive residual solvent if not completely removed, which not only affects product purity but also poses potential toxicity risks. If high-risk reagents (e.g., sulfonate compounds) are used during the purification process, genotoxic impurities with potential mutagenic or carcinogenic risks may be introduced. Even at very low levels (e.g., ppm), these impurities must be strictly controlled. Highly sensitive analytical methods (e.g., LC-MS/MS) need to be developed and validated for monitoring, which increases the complexity of process development and quality control.

• Issues: Residual acetonitrile, DMF, nitrosamines.
• Solutions: After TFA cleavage, perform cold diethyl ether precipitation to remove resin fragments, followed by ultrafiltration and concentration to reduce the load on subsequent purification steps.

 

Low separation efficiency

1.Small differences in hydrophobicity and charge

• Issue: Peptides have similar physicochemical properties, leading to peak tailing or overlap.
• Solution: Adjust the mobile phase pH close to the peptide's isoelectric point (e.g., pH 5 for exenatide) and use ion-pairing reagents (e.g., 0.1% TFA) to enhance resolution.

 

2.Improper selection of stationary phase

When selecting chromatographic column packing, considerations should include the peptide's molecular weight, hydrophobicity, and specific selectivity. For hydrophilic peptides with molecular weight below 4,000 Da, C18 columns usually provide good separation. For peptides larger than 5,000 Da with strong hydrophobicity, C4 columns are more suitable. C8 columns fall between C18 and C4, with performance leaning closer to C18. Additionally, for certain peptides requiring special selectivity, hydrophobic or polymer-based reversed-phase packing can be considered.

• Issue: C18 packing has insufficient capacity for long hydrophobic peptides, and silica-based packing has poor pH tolerance.
• Case: Tirzepatide was purified using polymer-based reversed-phase packing.

 

Bottlenecks in scale-up production

1.High solvent cost

• Issue: RP-HPLC relies heavily on acetonitrile, consuming up to 50 L/kg of peptide.
• Solution: Use aqueous two-phase purification (e.g., liraglutide PEG/ammonium sulfate system) to reduce organic solvent usage by 80%, or implement SMBC continuous-flow technology to lower consumption by 70%. Alternatively, replace reversed-phase chromatography with high-resolution ion-exchange or hydrophobic interaction chromatography.

 

2.Short column packing lifespan

• Issue: Silica-based packing allows only ~50 cycles, whereas polymer-based packing can exceed 200 cycles.
• Optimization: Perform alkali cleaning of the packing (e.g., 0.1 M NaOH) to increase capacity by 30%. The usable cycles are several times higher than silica, and the loading capacity is also greater than that of silica-based packing.

 

Stability and storage issues

1.Degradation and aggregation risk

• Issue: Environmental conditions during purification (e.g., pH fluctuations, temperature increases, exposure to oxygen or light) can trigger degradation of the target peptide, generating new impurities. For example, peptides containing methionine are prone to oxidation, forming sulfoxide or sulfone impurities; asparagine residues can undergo deamidation under certain pH conditions. These degradation products may appear in the later stages of purification and are structurally diverse, posing challenges for detection and control.
• During concentration, ultrafiltration, or exposure to air-liquid interfaces, peptide molecules are prone to physical aggregation, forming soluble or insoluble aggregates. These aggregates are difficult to remove by conventional filtration or chromatography and may induce immunogenic responses, making them a critical focus and challenge in biopharmaceutical quality control.
• Problem: Peptides are prone to oxidation, aggregation, or hydrolysis.
• Solution: Rapid lyophilization (store at -80 °C), avoid repeated freeze-thaw cycles, and convert TFA salts to acetate salts (e.g., insulin shows improved stability after lyophilization).

 

2.Poor solubility

• Issue: Hydrophobic peptides are difficult to dissolve in water.
• Strategy: Dissolve acidic peptides in 0.1% ammonia solution; adjust basic peptides with acetic acid; extremely hydrophobic peptides can be first dissolved in DMSO and then diluted.

 

Challenges in detection and analysis

1.Confusion between purity and content

• Issue: HPLC shows 99% purity, but the actual peptide content is only 70–80% (including water and salts).
• Solution: Determine the true content using nitrogen analysis or amino acid quantification.

 

2.Baseline drift and column efficiency decline

• Cause: TFA gradient elution causes UV absorption fluctuations, and silica columns exhibit non-specific adsorption.
• Optimization: Use a detection wavelength near 215 nm, and reduce TFA concentration in solvent B by ~15% compared to solvent A (e.g., 0.085%).

 

Process optimization strategies

 

Issues	Solutions	Reference case
Low recovery	Dynamic gradient design (e.g., gradient optimization for semaglutide increased yield by 14%)	Tirzepatide two-step RP-HPLC total yield: 74.35%
Residual solvents	One-step desalting using OSN membrane (recovery >95%)	Tirzepatide purification: acetonitrile consumption reduced by 40%
Low impurity removal efficiency	Pre-purification (e.g., ion-exchange column captures 75% of impurities)	GLP-1 combined IEC + RP-HPLC purification: purity >99.6%

 

Future development directions

1.Green approaches: Use biodegradable packing materials (e.g., polylactide-based) and replace acetonitrile with γ‑valerolactone.

2.Intelligent approaches: Apply AI to predict optimal elution conditions (e.g., DeepMind tool optimized exenatide pH to 5).

3.Continuous-flow technology: SMBC systems enable kilogram-scale production while reducing solvent consumption by 70%.

 

Summary: The core challenges in peptide purification lie in impurity control and process economy. High-efficiency, low-cost purification can be achieved through technological innovations (e.g., polymer-based packing, combined chromatography techniques) and process optimization (e.g., solvent recycling, continuous production).